Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003434 · ClinicalTrials.gov registry record · Phase 1
Biological Therapy in Stage I, Stage II, or Stage III Surgically Resected Pancreatic Cancer
A Phase 1 study, sponsored by Duke University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT00003434: Clinical Trial Phase 1 study, sponsored by Duke University.
NCT00003434 is a Phase 1 study that was terminated before completion, run by Duke University. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003434, a Phase 1 study, was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
Rational: White blood cells that have been treated with carcinoembryonic antigen peptide-1 may help the body build an immune response to and kill tumor cells that express CEA. Purpose: Phase II trial to study the effectiveness of white blood cells plus carcinoembryonic antigen peptide-1 in treating patients with stage I, stage II, or stage III pancreatic cancer that has been surgically removed.
Interventions
- BIOLOGICAL carcinoembryonic antigen peptide 1
- BIOLOGICAL hepatitis B antigen peptide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 1998-06 |
| Est. Completion | 2002-08 |
| Phase | Phase 1 |
Why NCT00003434 stopped before completion
NCT00003434 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 2 interventions - of which carcinoembryonic antigen peptide 1 is the first listed.
NCT00003434 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003434 about?
NCT00003434 is a clinical study titled "Biological Therapy in Stage I, Stage II, or Stage III Surgically Resected Pancreatic Cancer". Rational: White blood cells that have been treated with carcinoembryonic antigen peptide-1 may help the body build an immune response to and kill tumor cells that express CEA. Purpose: Phase II trial to study the effectiveness of white blood cells plus carcinoembryonic antigen peptide-1 in treating...
What is the current status of trial NCT00003434?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 1998-06. Estimated completion is 2002-08.
What interventions are being tested in trial NCT00003434?
The interventions under investigation include: carcinoembryonic antigen peptide 1 (BIOLOGICAL), hepatitis B antigen peptide (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003434?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00003434's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia